114 related articles for article (PubMed ID: 30715891)
21. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
[TBL] [Abstract][Full Text] [Related]
22. The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine.
Fujioka Y; Ueki H; A R; Sasajima A; Tomono T; Ukawa M; Yagi H; Sakuma S; Kitagawa K; Shirakawa T
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892182
[TBL] [Abstract][Full Text] [Related]
23. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
24. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
25. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
26. Performance of cell-penetrating peptide-linked polymers physically mixed with poorly membrane-permeable molecules on cell membranes.
Sakuma S; Suita M; Yamamoto T; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Hashizume A; Tachikawa H; Kimura R; Ishimaru Y; Kasai A; Maeda S
Eur J Pharm Biopharm; 2012 May; 81(1):64-73. PubMed ID: 22306700
[TBL] [Abstract][Full Text] [Related]
27. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.
Bradney CP; Sempowski GD; Liao HX; Haynes BF; Staats HF
J Virol; 2002 Jan; 76(2):517-24. PubMed ID: 11752142
[TBL] [Abstract][Full Text] [Related]
28. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
Abe N; Kodama S; Hirano T; Eto M; Suzuki M
Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
[TBL] [Abstract][Full Text] [Related]
29. Intranasal and sublingual delivery of inactivated polio vaccine.
Kraan H; Soema P; Amorij JP; Kersten G
Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant.
Mariotti S; Teloni R; von Hunolstein C; Romagnoli G; Orefici G; Nisini R
Vaccine; 2002 May; 20(17-18):2229-39. PubMed ID: 12009277
[TBL] [Abstract][Full Text] [Related]
31. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
32. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
Qin T; Yin Y; Huang L; Yu Q; Yang Q
Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
[TBL] [Abstract][Full Text] [Related]
33. A Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway.
Fukasaka M; Asari D; Kiyotoh E; Okazaki A; Gomi Y; Tanimoto T; Takeuchi O; Akira S; Hori M
PLoS One; 2015; 10(5):e0126849. PubMed ID: 25978818
[TBL] [Abstract][Full Text] [Related]
34. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
[TBL] [Abstract][Full Text] [Related]
35. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
36. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
37. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
[TBL] [Abstract][Full Text] [Related]
38. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.
Watanabe I; Ross TM; Tamura S; Ichinohe T; Ito S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
Vaccine; 2003 Nov; 21(31):4532-8. PubMed ID: 14575764
[TBL] [Abstract][Full Text] [Related]
39. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
40. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
Uppada SB; Bhat AA; Sah A; Donthamshetty RN
Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]